Evidence map›Paper›PMID 35424170›Full record

ReviewRSC advances2021

Organic dots (O-dots) for theranostic applications: preparation and surface engineering.

Amin Shiralizadeh Dezfuli, Elmira Kohan, Sepand Tehrani Fateh, Neda Alimirzaei, Hamidreza Arzaghi, Michael R Hamblin

Open access · goldAbstract readReview
In one paragraph

Review in RSC advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 4 countries.

Amin Shiralizadeh DezfuliPhysiology Research Center, Iran University of Medical Sciences Tehran Iran amindezfuli@outlook.com.ORCID https://orcid.org/0000-0001-8628-3010
Elmira KohanDepartment of Science, University of Kurdistan Kurdistan Sanandaj Iran.
Sepand Tehrani FatehSchool of Medicine, Shahid Beheshti University of Medical Sciences (SBMU) Tehran Iran.
Neda AlimirzaeiInstitute of Nanoscience and Nanotechnology, University of Kashan Kashan Iran.
Hamidreza ArzaghiDepartment of Medical Biotechnology, Faculty of Allied Medical Sciences, Iran University of Medical Sciences (IUMS) Tehran Iran.ORCID https://orcid.org/0000-0001-9592-115X
Michael R HamblinWellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School Boston MA 02114 USA.ORCID https://orcid.org/0000-0001-6431-4605
Iran University of Medical Sciences · IRHarvard University · USIndiana University School of MedicineIslamic Azad University Sanandaj Branch · IRUniversity of Kashan · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Organic dots is a term used to represent materials including graphene quantum dots and carbon quantum dots because they rely on the presence of other atoms (O, H, and N) for their photoluminescence or fluorescence properties. They generally have a small size (as low as 2.5 nm), and show good photostability under prolonged irradiation. The excitation and emission wavelengths of O-dots can be tailored according to their synthetic procedure, where although their quantum yield is quite low compared with organic dyes, this is partly compensated by their large absorption coefficients. A wide range of strategies have been used to modify the surface of O-dots for passivation, improving their solubility and biocompatibility, and allowing the attachment of targeting moieties and therapeutic cargos. Hybrid nanostructures based on O-dots have been used for theranostic applications, particularly for cancer imaging and therapy. This review covers the synthesis, physics, chemistry, and characterization of O-dots. Their applications cover the prevention of protein fibril formation, and both controlled and targeted drug and gene delivery. Multifunctional therapeutic and imaging platforms have been reported, which combine four or more separate modalities, frequently including photothermal or photodynamic therapy and imaging and drug release.

Identifiers

PMID35424170
PMCPMC8693874
OpenAlexW3118331647

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.